Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

N/ACompletedNCT00638391

AstraZeneca1,600 enrolled

Overview

The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.

Study Type

OBSERVATIONAL

Enrollment

1,600

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal women with early hormone receptor positive breast cancer/no metastasis Exclusion Criteria: * None

evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions

Time frame: 12 months

description of population treated with anastrozole

Time frame: 12 months

further information about the change of specific laboratory parameters

Time frame: 12 months

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.